MOSCOW (MRC) -- Scientific instrumentation equipment maker Thermo Fisher Scientific Inc. is investing USD140 million to expand its existing laboratory plastics production to support global demand for COVID-19 testing and the development of therapies and vaccines, said Canplastics.
"Early in the pandemic, we quickly joined forces with governments, public health agencies and industry to increase capacity across our laboratory plastics production facilities and address the growing COVID-19 threat,” said Fred Lowery, senior vice president and president of Life Sciences Solutions and Laboratory Products at Thermo Fisher. “However, demand quickly exceeded those early expansion projects, so we began a series of additional expansions to meet the growing needs of our customers. These investments, along with many others across the company, will ensure that our customers have the supplies they need to continue meeting the unprecedented demands of the COVID-19 response."
The rapid increase in production related to COVID-19 testing, and development and manufacturing of therapies and vaccines, has created what the company calls “historic demand for laboratory plastics”, including pipette and automation tips, storage tubes and plates, transfer pipettes, and packaging vials and bottles. To support these needs, Waltham, Mass.-based Thermo Fisher is creating more than 1,000 jobs across manufacturing sites globally, increasing automation capabilities, and optimizing warehouse and sterilization capacity to improve supply chain agility.
Among the Thermo Fisher sites currently being expanded are Rochester, N.Y.; Petaluma, Calif.; Monterrey and Tijuana, Mexico; and Joensuu, Finland.
This latest investment comes on the heels of Thermo Fisher’s opening last month of a new US$40 million facility in Lenexa, Kan., for viral transport media production to meet sustained demand for COVID-19 testing.
As MRC informed earlier, European Parliament says that the EU should become more self-sufficient in medicines and medical equipment so that affordable treatments are available at any time. It calls for priority to be given to boosting domestic production of essential and strategic medicines because currently 40% of medicines marketed in the EU originate in non-EU countries and 60-80% of its active pharmaceutical ingredient (API) supplies are produced in China and India.
According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.